Atria Investments Inc Has $7.30 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Atria Investments Inc lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,793 shares of the company’s stock after acquiring an additional 1,659 shares during the period. Atria Investments Inc’s holdings in IDEXX Laboratories were worth $7,302,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories in the third quarter valued at about $31,000. Finally, Greykasell Wealth Strategies Inc. acquired a new position in IDEXX Laboratories in the third quarter valued at about $35,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on IDXX shares. Barclays dropped their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $528.79 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $496.61 and a 12-month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average price is $572.08 and its two-hundred day moving average price is $645.56. The stock has a market cap of $41.71 billion, a PE ratio of 38.94, a P/E/G ratio of 3.10 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business posted $2.91 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 34,612 shares of company stock valued at $22,525,070. Company insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.